ACAD Acadia Pharmaceuticals Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
21:01
Aug 02
Aug 02
r/ValueInvesting
ACAD has zero crippling debt, high margins, and double-digit revenue growth.
ACAD has zero crippling debt, high margins, and double-digit revenue growth. Solid commercial execution (Nuplazid/Daybue) meets strict value and growth criteria. The author holds a position, noting it surprisingly passes all strict biotech hurdles. Clinical trial risks or regulatory hurdles typical of the biotech sector.
ACAD
Acadia Pharmaceuticals Inc.
Long
1ST
—
—
21:50
Jan 12
Jan 12
Bloomberg Markets
Acadia positioned well in neuroscience/rare disease.
Acadia is focused on neurological disease and rare disease, where it can address patient communities with few options. She says the company remains committed to this area despite policy changes, is not disrupted by government research funding cuts, and engages with policymakers; it also has strong patient-support programs and received approval for a new formulation in December.
ACAD
Acadia Pharmaceuticals Inc.
Long
1ST
—
—
About ACAD Investor Commentary
Across the available history and selected sources, Buzzberg tracks ACAD (Acadia Pharmaceuticals Inc.) across 4 sources: 2 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Latest voices: u/LectureForsaken6782, Catherine Owen Adams.